Prospective trial on focal treatment with hemi-gland brachytherapy in low-risk prostate cancer: A negative study
In this trial, patients treated with hemi-gland brachytherapy had significantly higher biochemical failure and contralateral relapse rates than a historical cohort of patients treated with WGBT. Larger, well-designed clinical trials are needed to better assess the efficacy of HGBT in the treatment of low-risk PCa.
Authors
- Pablo Araguás
- Montse Ferrer (ORCID: https://orcid.org/0000-0001-9867-7391)
- Naiara Fuentemilla
- Andrea Slocker
- Marta Barrado
- S. Pellejero (ORCID: https://orcid.org/0000-0003-2070-4542)
- Ignacio Visus (ORCID: https://orcid.org/0000-0001-6627-546X)
- Olatz Garín (ORCID: https://orcid.org/0000-0001-6193-0779)
- Montse Ventura (ORCID: https://orcid.org/0000-0002-3366-8360)
- Cristina Gutiérrez (ORCID: https://orcid.org/0000-0002-6944-772X)
- A. Sola
- E. Villafranca
- Margarita Illas
- D. Najjari
- Francisco Pino (ORCID: https://orcid.org/0009-0002-2781-9342)
Institutions
- Universitat Pompeu Fabra (ES)
- Institut Català d'Oncologia (ES)
- Hospital Del Mar (ES)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
Publication Details
- Journal
- Journal of Contemporary Brachytherapy
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5114/jcb.2025.156000
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00